Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 14 years, it is emailed twice daily to more than 11,000 pharma industry professionals throughout Australia and NZ.

For just $454.50 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Perspective
Queue for PBS listing stretches back years
With drugs waiting in the wings for PBS listing more than two and a half years after being recommended, the road to reimbursement remains a long and winding one and for some, it's a road to nowhere.
Approvals Action
Pfizer registers meningo B vax
Pfizer has registered meningococcal B vax Trumenba on the ARTG making it the second vaccine for the disease after GSK's Bexsero.
Pipeline Monitor
GSK, AZ gear up for COPD filing
Big data readouts this week saw GSK and AstraZeneca confirming they would file existing drugs in the COPD space within the next 12 months.